CD101, a novel echinocandin, possesses potent antibiofilm activity against early and mature Candida albicans biofilms
Open accessAbstract
Currently available echinocandins are generally effective against Candida biofilms, but the recent emergence of resistance has underscored the importance of developing new antifungal agents that are effective against biofilms. CD101 is a long-acting novel echinocandin with distinctive pharmacokinetic properties and improved stability and safety relative to other drugs in the same class. CD101 is currently being evaluated as a once-weekly intravenous (i.v.) infusion for the treatment of candidemia and invasive candidiasis. In this study, we determined (i) the effect of CD101 against early and mature phase biofilms formed by C. albicans in vitro and (ii) the temporal effect of CD101 on the formation of biofilms using time-lapse microscopy (TLM). Early- or mature-phase biofilms were formed on silicone elastomer discs and were exposed to the test compounds for 24 h and quantified by measuring their metabolic activity. Separate batches were observed under a confocal microscope or used to capture TLM images from 0 to 16 h. Measurements of their metabolic activity showed that CD101 (0.25 or 1 μg/ml) significantly prevented adhesion-phase cells from developing into mature biofilms ( P = 0.0062 or 0.0064, respectively) and eradicated preformed mature biofilms ( P = 0.04 or 0.01, respectively) compared to those of untreated controls. Confocal microscopy showed significant reductions in biofilm thicknesses for both early and mature phases ( P < 0.05). TLM showed that CD101 stopped the growth of adhesion- and early-phase biofilms within minutes. CD101-treated hyphae failed to grow into mature biofilms. These results suggest that CD101 may be effective in the prevention and treatment of biofilm-associated nosocomial infections.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rezafungin is active against C. albicans biofilms, inhibiting biofilm formation and being effective against mature biofilms.
“Consistent with previous studies of echinocandins, rezafungin is also active against C. albicans biofilms, as treatment with this drug both inhibits biofilm formation and is affective against mature biofilms [42].”
From Antifungal therapy of Candida biofilms: Past, present and future (2023) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Chandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578 · see citing works
Self-citationBiofilms and Device-Associated Infections
Donlan, R. M. (2001) · Emerging infectious diseases · doi:10.3201/eid0702.010226 · Cited by 1,425 · see citing works
Candida biofilms and their role in infection
Douglas, L. J. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(02)00002-1 · Cited by 1,150 · see citing works
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · see citing works
Kuhn, D. M., George, T., Chandra, J., Mukherjee, P. K., & Ghannoum, M. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1773-1780.2002 · Cited by 765 · see citing works
Self-citationMukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511 · see citing works
Self-citationLarkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02396-16 · Cited by 395 · see citing works
Self-citationCurrent Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274 · see citing works
Genetic Basis of<i>Candida</i>Biofilm Resistance Due to Drug‐Sequestering Matrix Glucan
Nett, J. E., Sanchez, H., Cain, M. T., & Andes, D. R. (2010) · The Journal of Infectious Diseases · doi:10.1086/651200 · Cited by 250 · see citing works
In vitro growth and analysis of Candida biofilms
Chandra, J., Mukherjee, P. K., & Ghannoum, M. A. (2008) · Nature Protocols · doi:10.1038/nprot.2008.192 · Cited by 247 · see citing works
Self-citationCandida biofilms: antifungal resistance and emerging therapeutic options.
Kuhn, D. M., & Ghannoum, M. A. (2004) · PubMed · Cited by 166 · see citing works
Self-citationSafety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161 · see citing works
Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum, M. A., & Kuhn, D. M. (2002) · PubMed · Cited by 150 · see citing works
Self-citationEchinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145 · see citing works
Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
Ong, V. S., Hough, G., Schlosser, M., Bartizal, K. F., Balkovec, J. M., James, K. D., & Krishnan, B. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-16 · Cited by 126 · see citing works
Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms
Mitchell, K. F., Taff, H. T., Cuevas, M. A., Reinicke, E. L., Sanchez, H., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02378-12 · Cited by 104 · see citing works
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Jones, R. N., & Castanheira, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw214 · Cited by 103 · see citing works
Zhao, Y., Prideaux, B., Nagasaki, Y., Lee, M. H., Chen, P.-Y., Blanc, L., Ho, H., Clancy, C. J., Nguyen, M. H., Dartois, V., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-17 · Cited by 102 · see citing works
CD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81 · see citing works
Locke, J. B., Almaguer, A. L., Zuill, D. E., & Bartizal, K. F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00620-16 · Cited by 66 · see citing works
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.03.028 · Cited by 65 · see citing works
Fekkar, A., Dannaoui, É., Meyer, I., Imbert, S., Brossas, J., Uzunov, M., Mellon, G., Nguyen‐Quoc, S., Guiller, E., Caumes, É., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2096-9 · Cited by 63 · see citing works
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02045-16 · Cited by 53 · see citing works
Harputlu, D., & Özsoy, S. A. (2018) · Wound Management & Prevention · doi:10.25270/owm.2018.10.1830 · Cited by 51 · see citing works
Kovács, R., Bozó, A., Gesztelyi, R., Domán, M., Kardos, G., Nagy, F., Tóth, Z., & Majoros, L. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.01.007 · Cited by 51 · see citing works
Saye, D. E. (2007) · PubMed · Cited by 43 · see citing works
Kaneko, Y., Miyagawa, S., Takeda, O., Hakariya, M., Matsumoto, S., Ohno, H., & Miyazaki, Y. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02290-12 · Cited by 36 · see citing works
Catheter‐Related Bloodstream Infections in HIV‐Infected Patients
Nicastri, E., Petrosillo, N., Viale, P., & Ippolito, G. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03917.x · Cited by 32 · see citing works
Fofana, M. O., Shrestha, S., Knight, G. M., Cohen, T., White, R. G., Cobelens, F. G. J., & Dowdy, D. W. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00498-16 · Cited by 29 · see citing works
Marcos-Zambrano, L. J., Escribano, P., Bouza, E., & Guinea, J. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw162 · Cited by 19 · see citing works
Castanheira, M., Messer, S., Rhomberg, P., Jones, R. J., & Pfaller, M. A. (2014) · Cited by 9 · see citing works
Lepak, A. J., Zhao, M., VanScoy, B. D., Ambrose, P. G., & Andes, D. R. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1224 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Oral Candidiasis: A Disease of Opportunity
Vila, T., Sultan, A. S., Montelongo-Jauregui, D., & Jabra-Rizk, M. A. (2020) · Journal of Fungi · doi:10.3390/jof6010015 · Cited by 537 · see citing works
Echinocandins – structure, mechanism of action and use in antifungal therapy
Szymański, M., Chmielewska, S., Czyżewska, U., Malinowska, M., & Tylicki, A. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2050224 · Cited by 281 · see citing works
Antifungal drugs: What brings the future?
Daele, R. V., Spriet, I., Wauters, J., Maertens, J. A., Mercier, T., Hecke, S. V., & Brüggemann, R. J. M. (2019) · Medical Mycology · doi:10.1093/mmy/myz012 · Cited by 223 · see citing works
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works
García‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 134 · see citing works
Beardsley, J., Halliday, C. L., Chen, S. C. ‐., & Sorrell, T. C. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0059 · Cited by 126 · see citing works
Prasath, K. G., Tharani, H., Kumar, M. S., & Pandian, S. K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00864 · Cited by 111 · see citing works
Review on Current Status of Echinocandins Use
Mroczyńska, M., & Brillowska‐Dąbrowska, A. (2020) · Antibiotics · doi:10.3390/antibiotics9050227 · Cited by 108 · see citing works
Sofjan, A. K., Mitchell, A. C., Shah, D. N., Nguyen, T. H., Sim, M., Trojcak, A., Beyda, N. D., & Garey, K. W. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.02.013 · Cited by 99 · see citing works
Fungal biofilms in human health and disease
Ramage, G., Kean, R., Rautemaa-Richardson, R., Williams, C., & Lopez-Ribot, J. L. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01147-0 · Cited by 72 · see citing works
Pfaller, M. A., Carvalhaes, C., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-20 · Cited by 68 · see citing works
Combination Therapy to Treat Fungal Biofilm-Based Infections
Tits, J., Cammue, B. P. A., & Thevissen, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228873 · Cited by 70 · see citing works
Rezafungin: a novel antifungal for the treatment of invasive candidiasis
Ham, Y. Y., Lewis, J. S., & Thompson, G. R. (2021) · Future Microbiology · doi:10.2217/fmb-2020-0217 · Cited by 66 · see citing works
Antifungal therapy of Candida biofilms: Past, present and future
Ajetunmobi, O. H., Badali, H., Romo, J. A., Ramage, G., & Lopez-Ribot, J. L. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100126 · Cited by 52 · see citing works
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective
Ordaya, E. E., Clement, J., & Vergidis, P. I. (2023) · Mycopathologia · doi:10.1007/s11046-023-00759-5 · Cited by 37 · see citing works
Silva, L. N., de Mello, T. P., Ramos, L. S., Branquinha, M. H., & dos Santos, A. L. S. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191025152412 · Cited by 27 · see citing works
Peng, Z., & Tang, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.783010 · Cited by 21 · see citing works
Rezafungin in special populations with candidaemia and/or invasive candidiasis
Cornely, O. A., Dupont, H., Mikulska, M., Rautemaa‐Richardson, R., García‐Vidal, C., Thompson, G. R., & Hoenigl, M. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106435 · Cited by 19 · see citing works
Ponta, G., Morena, V., Strano, M., Molteni, C., Pontiggia, S., Cavalli, E. M., Grancini, A., Mauri, C., Castagna, A., Galanti, A., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00750-24 · Cited by 18 · see citing works
Perrine-Walker, F. M. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-022-00739-9 · Cited by 19 · see citing works
Ceballos-Garzón, A., Lebrat, J., Holzapfel, M., Josa, D. F., Welsch, J., & Mercer, D. K. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00137-25 · Cited by 18 · see citing works
Modeling Bacterial Attachment Mechanisms on Superhydrophobic and Superhydrophilic Substrates
Cavitt, T. B., & Pathak, N. (2021) · Pharmaceuticals · doi:10.3390/ph14100977 · Cited by 15 · see citing works
Squitieri, D., Rizzo, S., Torelli, R., Mariotti, M., Sanguinetti, M., Cacaci, M., & Bugli, F. (2025) · Pharmaceuticals · doi:10.3390/ph19010008 · Cited by 11 · see citing works
Sharma, D., & Vázquez, J. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2331775 · Cited by 11 · see citing works
Rezafungin Utilisation in Real Life— FungiScope Results From Europe and the United States
Reinhold, I., Mori, G., Lanzafame, M., Limongelli, A., Vena, A., Götz, J., Bauernfeind, S., Hanses, F., Tometten, L., Mayer, M., et al. (2025) · Mycoses · doi:10.1111/myc.70114 · Cited by 10 · see citing works
Bassetti, M., Stewart, A. G., Bartalucci, C., Vena, A., Giacobbe, D. R., & Roberts, J. A. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2424899 · Cited by 9 · see citing works
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
August, B., & Kale-Pradhan, P. B. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2926 · Cited by 8 · see citing works
Siddharthan, S., Shafreen, R. B., & Gopal, V. (2020) · Archives of Microbiology · doi:10.1007/s00203-020-01918-8 · Cited by 8 · see citing works
Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin
Kmet, N. G., Luzzati, R., Monticelli, J., Babich, S., Conti, J., & Bella, S. D. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05117-5 · Cited by 4 · see citing works
Current and emerging therapies for fungal biofilms and systemic infections
Elgammal, Y., Martinez, R. I. G., Requejo, A., & Martinez, L. R. (2025) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2025.2570185 · Cited by 4 · see citing works
Safety and efficacy of echinocandin antifungal agents in Candida albicans endophthalmitis
Zhang, Y., Tang, Y. R., Zhou, Y., & Wu, H. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01670-25 · Cited by 2 · see citing works
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Zubovskaia, A., & Vázquez, J. A. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s547511 · Cited by 2 · see citing works
Ramage, G., Kean, R., Mackay, W. G., Vaccaro, A., Lopez-Ribot, J. L., & Howe, M. H. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_7 · Cited by 1 · see citing works
Real-world experience with rezafungin for the treatment of biofilm-forming Candida infections
Albanell‐Fernández, M., Soriano, À., Herrera, S., Tuset, M., Arranz, N., Deckers, C., & Honoré, P. M. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2604475 · Cited by 2 · see citing works
Rezafungin in fluconazole-resistant and refractory candidiasis: the first Brazilian experience
Kruschewsky, W. L. L., Nakagawa, J. A. D. S., Siqueira, L. P. M., Taborda, M., de Oliveira, V. F., Abdala, E., Magri, A. S. G. K., & Magri, M. M. C. (2026) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202668020 · Cited by 1 · see citing works
Antifungal activity of rezafungin in invasive candidiasis: From bench to bed
Quindós, G., García‐Vidal, C., Martin-Martitegui, X., & Zaragoza, R. (2026) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2026.02.001
- Authors
- Chandra, J., & Ghannoum, M. A.
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Corresponding author
- Ghannoum, Mahmoud A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-02
- Volume
- 62
- Issue
- 2
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5786756
- OpenAlex
- W2769338983
- Cited by
- 36
- References
- 32
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 5 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 7 · 2019: 2 · 2018: 2
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- CD101, echinocandins, Candida albicans, biofilm eradication, antifungal agents, candidemia, invasive candidiasis, biofilm inhibition, hyphal growth, biofilm thickness, antifungal resistance, nosocomial infections
- MeSH terms
- Antifungal Agents, Candida albicans, Candidiasis, Biofilms, Drug Resistance, Fungal, Echinocandins, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
